Targacept launches Phase II; Amylin touts blood sugar data; drug reduces craving for alcohol

> Targacept has launched a Phase II trial of a potential new therapy for ADHD. The drug targets receptors of neuronal nicotinic receptors. Report

> Amylin Pharmaceuticals released new data showing that patients taking Symlin with basal insulin lowered blood sugar levels more than a group taking rapid-acting insulin combined with basal insulin. Release

> Scientists say that an ingredient in garlic can beat MRSA. Report

> Another week, another big medical society meeting sending shock-waves--good and bad--through the pharma biz. This week, of course, it's the wrap-up of the American Diabetes Association confab. ADA report

> Lately it hasn't been a love-fest among analysts and investors and Big Pharma. A few drugmakers have won their kudos, but overall the mood has been somewhat grim. Not so today. Going contrarian, a BusinessWeek columnist touts Pfizer, and a former analyst is launching (drum roll, please) a pharma-based hedge fund. Report

> Just what Merck doesn't need: Its asthma-and-allergy med Singulair is losing ground, with new scrips down year-over-year for 13 weeks straight. Singulair report

> The FDA might finally get its $275 million in additional funding. Report

> Few disease targets are as attractive to drug developers as obesity. And few are as complex. Researchers and drug companies are routinely stumped in trying to develop a pill that can trump the body's 'guerrilla tactics' when it comes to weight loss. Obesity report

> Researchers at the University of Virginia say that an epilepsy drug--topiramate--can reduce alcoholics' craving for a drink as well as promote their overall health. Report

> So far this year a more vigilant FDA has barred seven physicians from conducting medical research work. FDA report

And Finally... Researchers at the University of Virginia say that an epilepsy drug - topiramate - can reduce alcoholics' craving for a drink as well as promote their overall health. Report

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.